Floatz logo

cm082

Advanced Malignant Solid Tumors

AnewPharmaPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

37 Active assets in the Advanced Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Neratinib
Puma Biotechnology, Inc.
Phase 1/2B
Capecitabine
Puma Biotechnology, Inc.
Phase 1/2B
TRASTUZUMAB
Puma Biotechnology, Inc.
Phase 1/2B
Vinorelbine
Puma Biotechnology, Inc.
Phase 1/2B
Trastuzumab Emtansine
Puma Biotechnology, Inc.
Phase 1/2B

View all 50 →

Same molecule, other indications

cm082 is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
mucosal melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →